Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that increasing use of emerging antidepressants will fuel growth in the chronic low back pain market due to the ability of these therapies to address both pain and comorbid depression.

According to the new Pharmacor study entitled Chronic Low Back Pain, Eli Lilly's duloxetine and DOV Pharmaceutical's bicifadine will garner significant sales as the first antidepressants to receive approval for pain. These promising new drugs will fill the void left by the declining sales of the COX- 2 inhibitors, which previously dominated the chronic low back pain market.

"Drug companies are turning to chronic pain for new commercial opportunities because markets traditionally targeted by antidepressant manufacturers -- such as major depression and anxiety disorders -- are now saturated," said Elana Feldman, analyst at Decision Resources. "Chronic low back pain is a particularly attractive indication because of its large patient population."

About Chronic Low Back Pain

Chronic low back pain is a highly prevalent condition that is estimated to affect more than 30 million individuals in the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Despite the fact that a large number of sufferers remain undiagnosed and/or untreated, the chronic low back pain therapy market reached nearly $2.4 billion in 2004.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Therapies from Gilead and Bristol-Myers Squibb Will Expand the HIV Market

View Now